TPWA
CRNX

Twin Peaks Wealth Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7
Closed -$254 – 661
2026
Q1 		$254 Buy
+7
New +$313 ﹤0.01% 2139
2025
Q3 		– Sell
-6
Closed -$171 – 587
2025
Q2 		$171 Buy
+6
New +$185 ﹤0.01% 2051

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Twin Peaks Wealth Advisors's CRNX Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 7 shares — an estimated $254 sold.

Twin Peaks Wealth Advisors first reported a position in CRNX in Q2 2025 and held it in 2 quarters. The position peaked at $254 in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 7 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $254.
  • Twin Peaks Wealth Advisors first reported a position in Crinetics Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Crinetics Pharmaceuticals position peaked at $254 in Q1 2026.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.